Page last updated: 2024-11-02

moxonidine and Insulin Sensitivity

moxonidine has been researched along with Insulin Sensitivity in 21 studies

moxonidine: structure given in first source

Research Excerpts

ExcerptRelevanceReference
" Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase."9.14Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010)
"To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome."9.12Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006)
"Moxonidine is useful and safe for controlling arterial hypertension in obese patients."9.11Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005)
"To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension."9.09Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999)
"A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome."7.77Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome. ( Borodulina, EV; Gridneva, TD; Kseneva, SI; Kulakova, NV; Semiglazova, TA; Tarasova, IV; Trifonova, OJ; Udut, VV, 2011)
" In dose-response experiments, the maximal response (E(max)) was markedly reduced 18."5.34Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007)
"The short-term effects of two sympatholytic antihypertensive drug treatments, β-blocking agent atenolol and imidazoline receptor-1 agonist moxonidine, on postmenopausal symptoms and their relationship to antihypertensive and insulin sensitivity effect were studied."5.19Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women. ( Kaaja, RJ; Kujala, SM; Pöyhönen-Alho, M, 2014)
" Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase."5.14Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010)
" We compared the effect of two sympatholytic antihypertensive drug treatments, the centrally acting imidazoline receptor-1 agonist moxonidine and peripherally acting beta-blocking agent atenolol on sensitive inflammatory markers in overweight postmenopausal women with diastolic hypertension."5.13Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. ( Antikainen, RL; Ebeling, PE; Erkkola, RU; Kaaja, RJ; Katzman, P; Kibarskis, A; Manhem, K; Pöyhönen-Alho, MK; Tuomilehto, JO, 2008)
"To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome."5.12Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006)
"Moxonidine is useful and safe for controlling arterial hypertension in obese patients."5.11Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005)
"To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension."5.09Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999)
"The I1-imidazoline receptor is a specific high-affinity binding site corresponding to a functional cell-surface receptor mediating the antihypertensive actions of moxonidine and other second-generation centrally-acting agents, and may play a role in countering insulin resistance in an animal model of metabolic syndrome X."4.79The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. ( Ernsberger, P; Friedman, JE; Koletsky, RJ, 1997)
"A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome."3.77Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome. ( Borodulina, EV; Gridneva, TD; Kseneva, SI; Kulakova, NV; Semiglazova, TA; Tarasova, IV; Trifonova, OJ; Udut, VV, 2011)
"The sympatholytic antihypertensive agent moxonidine, a centrally acting selective I1-imidazoline receptor modulator (putative agonist), may be beneficial in hypertensive patients with insulin resistance."3.69Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. ( Fogt, DL; Gödicke, J; Henriksen, EJ; Jacob, S; Youngblood, EB, 1997)
"Moxonidine has unique effects on a number of cell types through this unusual cellular site of action."2.48Pharmacological properties of the central antihypertensive agent, moxonidine. ( Brown-Bryan, TA; Edwards, LP; Ernsberger, P; McLean, L, 2012)
"It is urgent to treat hypertension in these patients with drugs that do not further impair glucose control."2.40Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. ( Lithell, HO, 1997)
"Moxonidine has been shown to improve glucose tolerance in man, probably by two different mechanisms, i."2.40Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. ( Hansson, L, 1998)
" In dose-response experiments, the maximal response (E(max)) was markedly reduced 18."1.34Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007)
"Moxonidine treatment enhanced the expression of IRS-1 protein in skeletal muscle by 74% in SHROB and 40% in SHR."1.30Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. ( Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1998)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (47.62)18.2507
2000's7 (33.33)29.6817
2010's4 (19.05)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kujala, SM1
Pöyhönen-Alho, M1
Kaaja, RJ2
Hausberg, M1
Hillebrand, U1
Kisters, K1
Pöyhönen-Alho, MK1
Manhem, K2
Katzman, P2
Kibarskis, A2
Antikainen, RL1
Erkkola, RU1
Tuomilehto, JO1
Ebeling, PE1
Masajtis-Zagajewska, A1
Majer, J1
Nowicki, M1
Edwards, LP1
Brown-Bryan, TA1
McLean, L1
Ernsberger, P5
Kseneva, SI1
Borodulina, EV1
Semiglazova, TA1
Kulakova, NV1
Tarasova, IV1
Trifonova, OJ1
Gridneva, TD1
Udut, VV1
Rayner, B1
Abellán, J1
Leal, M1
Hernández-Menárguez, F1
García-Galbis, JA1
Martínez-Pastor, A1
de Vinuesa, SG1
Luño, J1
Chazova, I1
Almazov, VA1
Shlyakhto, E1
Sun, Z1
Kaaja, R1
Kujala, S1
Antikainen, R1
Ylihärsilä, H1
Erkkola, R1
Tuomilehto, J1
Friedman, JE3
Koletsky, RJ3
Lithell, HO1
Henriksen, EJ1
Jacob, S1
Fogt, DL1
Youngblood, EB1
Gödicke, J1
Krentz, AJ1
Evans, AJ1
Hansson, L1
Ishizuka, T1
Liu, S1
Farrell, CJ1
Bedol, D1
Haenni, A1
Lithell, H1
Schachter, M1

Reviews

6 reviews available for moxonidine and Insulin Sensitivity

ArticleYear
Pharmacological properties of the central antihypertensive agent, moxonidine.
    Cardiovascular therapeutics, 2012, Volume: 30, Issue:4

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Central Nervous System; Heart Failure; Humans; Hyp

2012
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Current medical research and opinion, 2004, Volume: 20, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Cardiovascular Dis

2004
The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1997, Volume: 15, Issue:1

    Topics: Animals; Antihypertensive Agents; Binding Sites; Clonidine; Humans; Hypertension; Imidazoles; Imidaz

1997
Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1997, Volume: 15, Issue:1

    Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Humans; Hypertension; Imidazoles; Imidazoline

1997
Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives.
    Blood pressure. Supplement, 1998, Volume: 3

    Topics: Antihypertensive Agents; Humans; Hyperlipidemias; Hypertension; Imidazoles; Insulin Resistance; Obes

1998
Metabolic effects of moxonidine and other centrally acting antihypertensives.
    Diabetes, obesity & metabolism, 1999, Volume: 1, Issue:6

    Topics: Animals; Antihypertensive Agents; Diabetes Complications; Humans; Hypertension; Imidazoles; Insulin

1999

Trials

7 trials available for moxonidine and Insulin Sensitivity

ArticleYear
Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.
    Climacteric : the journal of the International Menopause Society, 2014, Volume: 17, Issue:4

    Topics: Atenolol; Blood Pressure; Body Mass Index; Double-Blind Method; Drug Monitoring; Female; Hot Flashes

2014
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.
    Journal of hypertension, 2008, Volume: 26, Issue:12

    Topics: Adiponectin; Antihypertensive Agents; Atenolol; C-Reactive Protein; Double-Blind Method; Female; Fin

2008
Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:4

    Topics: Adipokines; Adult; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Body Size; Chiti

2010
Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
    Kidney international. Supplement, 2005, Issue:93

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellit

2005
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:4

    Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; G

2006
Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:7

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Finland

2007
Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1999, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat

1999

Other Studies

8 other studies available for moxonidine and Insulin Sensitivity

ArticleYear
Addressing the relationship between sympathetic activity and inflammation.
    Journal of hypertension, 2008, Volume: 26, Issue:12

    Topics: Antihypertensive Agents; Atenolol; C-Reactive Protein; Female; Humans; Hypertension; Imidazoles; Inf

2008
Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome.
    Bulletin of experimental biology and medicine, 2011, Volume: 151, Issue:4

    Topics: Adrenocorticotropic Hormone; Antihypertensive Agents; Female; Humans; Hydrocortisone; Hypertension;

2011
Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 320, Issue:2

    Topics: Adipocytes; Animals; Dose-Response Relationship, Drug; Female; Glucose; Hypertension; Imidazoles; In

2007
Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.
    Hypertension (Dallas, Tex. : 1979), 1997, Volume: 30, Issue:6

    Topics: Animals; Antihypertensive Agents; Biological Transport; Blood Glucose; Body Weight; Fatty Acids, Non

1997
Selective imidazoline receptor agonists for metabolic syndrome.
    Lancet (London, England), 1998, Jan-17, Volume: 351, Issue:9097

    Topics: Antihypertensive Agents; Humans; Hypertension; Imidazoles; Imidazoline Receptors; Insulin Resistance

1998
[The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
    Deutsche medizinische Wochenschrift (1946), 1998, Aug-14, Volume: 123, Issue:33 Suppl

    Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hypertension; Imidazoles; Imidazoline Re

1998
Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
    Blood pressure. Supplement, 1998, Volume: 3

    Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Female; Hyperglycemia; Hypertension; Hypog

1998
Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
    Annals of the New York Academy of Sciences, 1999, Nov-18, Volume: 892

    Topics: Animals; Anti-Obesity Agents; Carrier Proteins; Disease Models, Animal; Endocrine System; Female; Hy

1999